FMS-like tyrosine kinase 3 inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 4, 2011, Pages 483-503

  Lee, Jongkook ^a   Paek, Seung Mann ^b   Han, Sun Young ^b  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Gyeongsang National University   (South Korea)

Author keywords

Acute myeloid leukemia; cancer; Flt3; small molecule kinase inhibitor

Indexed keywords

BENZOXAZOLE DERIVATIVE; CD135 ANTIGEN; DASATINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; INDOLE; LESTAURTINIB; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; QUINOLINE; QUINOXALINE; SORAFENIB; STAUROSPORINE; SUNITINIB; THIOPHENE;

ACUTE GRANULOCYTIC LEUKEMIA; PROTEIN BINDING; REVIEW;

ANIMALS; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; PATENTS AS TOPIC; POLYCYCLIC COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; THIOPHENES;

EID: 79952973352     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.560115     Document Type: Review

References (132)

1. Matthews W, Jordan CT, Wiegand GW, et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991;65:1143-52 (Pubitemid 121001328)
2. Namikawa R, Muench MO, Roncarolo MG. Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells 1996;14:388-95 (Pubitemid 26286260)
3. Shurin MR, Esche C, Lotze MT. FLT3: Receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev 1998;9:37-48 .A comprehensive review of the Flt3/FL system. (Pubitemid 28280535)
4. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-18 (Pubitemid 27019637)
5. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12:1333-7 (Pubitemid 28442377)
6. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9 (Pubitemid 32291491)
7. Mckenzie SB. Advances in understanding the biology and genetics of acute myelocytic leukemia. Clin Lab Sci 2005;18:28-37
8. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62 (Pubitemid 29451802)
9. Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol 2010;3:17 .Recent development of AML therapies.
10. Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992;80:2584-93
11. Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996;87:1089-96 (Pubitemid 26043536)
12. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97:89-94 (Pubitemid 32061246)
13. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9
14. Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 2005;19:1345-9 (Pubitemid 41136326)
15. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66 (Pubitemid 35177429)
16. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35 (Pubitemid 34627197)
17. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18 (Pubitemid 351620111)
18. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-84
19. Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: The combination matters-an analysis of 3082 patients. Blood 2008;111:2527-37
20. Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997;11:1442-6 (Pubitemid 27404382)
21. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004;103:1085-8 (Pubitemid 38129575)
22. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76 (Pubitemid 38596280)
23. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70
24. Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-45
25. Stone R, Fischer T, Paquette R, et al. A Phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have flt3 mutations is similar to those with wild-type FLT3 [abstract 634]. 51st American Society of Hematology (ASH) annual meeting and exposition; 5 - 8 December 2009; New Orleans, USA
26. Astex Therapeutics. Pharmaceutical combinations. WO2008001101; 2008
27. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
28. Kasper S, Breitenbuecher F, Hoehn Y, et al. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk Res 2008;32:1698-708
29. Grunberger T, Demin P, Rounova O, et al. Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood 2003;102:4153-8 (Pubitemid 37487002)
30. Lipka DB, Hoffmann LS, Heidel F, et al. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008;7:1176-84
31. Chao Q, Sprankle KG, Grotzfeld RM, et al. Identification of N-(5-tert-butylisoxazol- 3-yl)-N'-{4-[7-(2-morpholin-4- yl-ethoxy)imidazo[2 ,1-b][1,3] benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem 2009;52:7808-16
32. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92 .Second generation Flt3 inhibitor.
33. Cortes J, Foran J, Ghirdaladze D, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study [abstract 636]. 51st American society of hematology (ASH) annual meeting and exposition; 5 - 8 December 2009; New Orleans, USA
34. Guerrouahen BS, Futami M, Vaklavas C, et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010;16:1149-58
35. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007;21:439-45
36. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62
37. Sugen. Indolinone compounds for the treatment of disease. WO1996040116; 1996
38. Yee KW, O'farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002;100:2941-9
39. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763-7 (Pubitemid 37248845)
40. Patyna S, Laird AD, Mendel DB, et al. SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5:1774-82 (Pubitemid 44323245)
41. Sugen. Pyrrole substituted 2-indolinone protein kinase inhibitors. WO2001060814; 2001
42. Yamanouchi Pharmaceutical. Pharmaceutical composition containing 3-quinolin-2(1h)-ylidene indolin-2-one derivative as active component. JP2005145928; 2005
43. Amino N, Ideyama Y, Yamano M, et al. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res 2006;12:1630-8
44. Anygen. Indirubin derivatives having anticancer property against human cancer cell me. WO2005070416; 2005
45. Choi SJ, Moon MJ, Lee SD, et al. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett 2010;20:2033-7
46. Industrial Technology Research Institute. Azulene compounds. EP1918277; 2008
47. Ko CH, Chen CH, Lee O, et al. K01109, a potent, novel selective FLT-3 inhibitor for the treatment of acute myelogenous leukemia [abstract LB-219]. 2009 AACR Annual Meeting; 18 - 22 April 2009; Denver, USA
48. Johannes-Gutenberg Universitat Mainz. Use of 3-(indolyl)- or 3-(azaindolyl)-4- arylmaleimide derivatives in leukemia management. WO2009071620; 2009
49. Teller S, Kramer D, Bohmer SA, et al. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002;16:1528-34
50. Kyowa Hakko Kogyo. Indazole derivatives. WO2005012257; 2005
51. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17
52. Cortes J, Roboz GJ, Kantarjian H, et al. A phase i dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML [abstract 2967]. 50th American society of hematology (ASH) annual meeting and exposition; 6 - 9 December 2008; San Francisco, USA
53. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938-46
54. Abbott. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors. WO2004113304; 2004
55. Zhou J, Goh BC, Albert DH, Chen CS. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside. J Hematol Oncol 2009;2:33
56. Zhou J, Pan M, Xie Z, et al. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 2008;22:138-46
57. Bristol-Myers Squibb. Pyrrolotriazine kinase inhibitors. WO2007061882; 2007
58. SuperGen. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors. WO2008058126; 2008
59. Chen LS, Redkar S, Bearss D, et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150-7
60. Ariad Pharmaceuticals. Bicyclic heteroaryl compounds. WO2007075869; 2007
61. Amphora. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof. WO2005033102; 2005
62. The Pfahl Family Trust. Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases. WO2006130613; 2006
63. Novartis. Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors. WO2005047273; 2005
64. IRM. Compounds and compositions as protein kinase inhibitors. WO2006081172; 2006
65. Sugen. Treatment of platelet derived growth factor related disorders such as cancers. US5990141; 1999
66. Tse KF, Novelli E, Civin CI, et al. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001;15:1001-10 (Pubitemid 32717268)
67. Levis M, Tse KF, Smith BD, et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001;98:885-7
68. Gazit A, App H, Mcmahon G, et al. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem 1996;39:2170-7
69. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989;32:2344-52 (Pubitemid 19245898)
70. Tse KF, Allebach J, Levis M, et al. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002;16:2027-36 (Pubitemid 35203445)
71. Yissum Research Development Company of the Hebrew University of Jerusalem. PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same. WO2001034607; 2001
72. Gazit A, Yee K, Uecker A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003;11:2007-18 (Pubitemid 36379018)
73. Cor Therapeutics and Kyowa Hakko Kogyo. Quinazoline derivatives as kinase inhibitors. WO2002016351; 2002
74. Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002;1:421-32 (Pubitemid 41039123)
75. Pandey A, Volkots DL, Seroogy JM, et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 2002;45:3772-93 (Pubitemid 34856116)
76. Deangelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-81 (Pubitemid 44864544)
77. Clark JJ, Cools J, Curley DP, et al. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004;104:2867-72 .Study revealing the cause for inherent resistance to tandutinib. (Pubitemid 39434973)
78. Astrazeneca. Combination therapy for the treatment of cancer. WO2007132215; 2007
79. Oke A, Pearce D, Wilkinson RW, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009;69:4150-8
80. Grundy M, Seedhouse C, Shang S, et al. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 2010;9:661-72
81. Janssen. Synergistic modulation of Flt3 kinase using alkylquinolines and alkylquinazolines. WO2006135629; 2006
82. Signal Pharmaceuticals. Quinazoline analogs and related compounds and methods for treating inflammatory conditions. US5939421; 1999
83. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005;105:804-11 (Pubitemid 40070768)
84. Griessinger E, Imbert V, Lagadec P, et al. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia 2007;21:877-85 (Pubitemid 46672062)
85. Kirin. Quinoline and quinazoline derivatives and drugs containing the same. WO2001047890; 2001
86. Kirin. Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of Flt3 and medicinal compositions containing the same. WO2004039782; 2004
87. Nishioka C, Ikezoe T, Yang J, et al. Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 2008;111:5086-92
88. Komeno Y, Kurokawa M, Imai Y, et al. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia 2005;19:930-5 (Pubitemid 40862002)
89. Nishiyama U, Yoshino T, Ozai M, et al. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. Leuk Res 2006;30:1541-6 (Pubitemid 44573480)
90. Array Biopharma. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors. WO2008121687; 2008
91. Lopes De Menezes DE, Peng J, Garrett EN, et al. CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91 (Pubitemid 41003717)
92. Merck. Tyrosine kinase inhibitors. WO2003020699; 2003
93. Merck. Orally active salts with tyrosine kinase activity. WO2002032861; 2002
94. BASF. Tricyclic pyrazole derivatives. WO2000027822; 2000
95. Murata K, Kumagai H, Kawashima T, et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003;278:32892-8
96. SuperGen. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same. US20080226747; 2008
97. Xanthus Pharmaceuticals. Imidazoacridine compounds for treating FLT3-mediated disorders. WO2008016665; 2008
98. Kinetek. Heteropolycyclic inhibitors of protein kinases. US6514972; 2003
99. Zeng Z, Samudio IJ, Zhang W, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006;66:3737-46
100. Novartis. Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases. WO2003099771; 2003
101. Novartis. Diaryl urea derivatives in the treatment of protein kinase dependent diseases. WO2005051366; 2005
102. Weisberg E, Roesel J, Bold G, et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: Effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 2008;112:5161-70
103. TargeGen. Bi-aryl meta-pyrimidine inhibitors of kinases. WO2007053452; 2007
104. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20 (Pubitemid 351446195)
105. Celltech. 5-cyano-2-aminopyrimidine derivatives. WO2000078731; 2000
106. Emanuel S, Gruninger RH, Fuentes-Pesquera A, et al. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 2004;66:635-47 (Pubitemid 39329263)
107. Janssen. Aminopyrimidines as kinase modulators. WO2006135719; 2006
108. Gaul MD, Xu G, Kirkpatrick J, et al. 4-Amino-6-piperazin-1-yl-pyrimidine- 5- carbaldehyde oximes as potent FLT-3 inhibitors. Bioorg Med Chem Lett 2007;17:4861-5
109. Kyowa Hakko Kogyo. Protein kinase inhibitors. WO2007032445; 2007
110. Kyowa Hakko Kogyo. Anti-tumor agent. WO2005095382; 2005
111. Ishida H, Isami S, Matsumura T, et al. Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. Bioorg Med Chem Lett 2008;18:5472-7
112. Kiyoi H, Shiotsu Y, Ozeki K, et al. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res 2007;13:4575-82
113. Rigel Pharmaceuticals. Cycloalkyl substituted pyrimidinediamine compounds and their uses. WO2005118544; 2005
114. Mclaughlin J, Markovtsov V, Li H, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136:99-113
115. S.*Bio. Heterocycloalkyl substituted pyrimidine derivatives. WO2008140421; 2008
116. Abbott. Substituted 7, 8-dihydro-1hpyrimido [4,5-b] [1,4] diazepin-4-amines as kinase inhibitors. WO2006124813; 2006
117. Gracias V, Ji Z, Akritopoulou-Zanze I, et al. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2008;18:2691-5 (Pubitemid 351503877)
118. Ambit Biosciences. Urea derivatives as kinase modulators. WO2005048948; 2005
119. Janssen. Method of inhibiting FLT3 kinase. WO2007048088; 2007
120. Manthey CL, Johnson DL, Illig CR, et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/ FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 2009;8:3151-61
121. Akinion Pharmaceuticals. Pyrazine derivatives and their use as protein kinase inhibitors. WO2009095399; 2009
122. Eriksson A, Hoglund M, Lindhagen E, et al. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia. Biochem Pharmacol 2010;80:1507-16
123. Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-15 (Pubitemid 41039121)
124. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40 (Pubitemid 29196596)
125. Kelly L, Clark J, Gilliland DG. Comprehensive genotypic analysis of leukemia: Clinical and therapeutic implications. Curr Opin Oncol 2002;14:10-18 .Two-hit hypothesis. (Pubitemid 34072957)
126. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002;99:310-18
127. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80 (Pubitemid 32743979)
128. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92 (Pubitemid 40271173)
129. Von Bubnoff N, Engh RA, Aberg E, et al. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69:3032-41
130. Cools J, Mentens N, Furet P, et al. Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004;64:6385-9
131. Heidel F, Solem FK, Breitenbuecher F, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006;107:293-300 .Clinical importance of secondary mutation of Flt3. (Pubitemid 43053554)
132. Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: A quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-22